Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Uprosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 6/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 6/20 | 1.00 |
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | SGK1 | O00141 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uprosertib SCHEMBL168584 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| Uprosertib SCHEMBL29658441 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL25062541 | 0.94 | AKT1 (0.89) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL14823114 | 0.93 | AKT1 (0.87) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529493 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529507 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529610 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529392 | 0.90 | AKT1 (0.81) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL22827778 | 0.89 | AKT1 (0.80) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529501 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | claimed |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12343380-B2 | Expansion of TILs utilizing AKT pathways inhibitors | IOVANCE BIOTHERAPEUTICS, INC. | 2025-07-01 | — | — | US | disclosed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-10722484-B2 | Methods of cancer treatment | K-GEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | K-GEN THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-06-13 | — | — | US | disclosed |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | disclosed |
| EP-3370743-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | City of Hope (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017079528-A9 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017079528-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE (US) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | AKT1 98/4885AKT2 47/4885AKT3 103/4885 |
| US-20180320133-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | AKT1 3905/4885AKT2 3986/4885AKT3 3951/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | AKT1 129/4885AKT2 49/4885AKT3 112/4885 |
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | PRKCI, PRKCH, PRKCZ | AKT1 323/4885AKT2 191/4885AKT3 207/4885 |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | AKT1 108/4885AKT2 53/4885AKT3 82/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | AKT1 3905/4885AKT2 3986/4885AKT3 3951/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AKT1 153/4885AKT2 97/4885AKT3 177/4885 |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | CD69, CD209, ICOS | AKT1 4251/4885AKT2 3594/4885AKT3 3236/4885 |
| US-10722484-B2 | Methods of cancer treatment | PRKCI, PRKCH, PRKCZ | AKT1 323/4885AKT2 191/4885AKT3 207/4885 |
| US-12343380-B2 | Expansion of TILs utilizing AKT pathways inhibitors | LCK, NFATC1, ICOS | AKT1 25/4885AKT2 8/4885AKT3 10/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | AKT1 2409/4885AKT2 2408/4885AKT3 3463/4885 |
| US-20210102165-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | AKT1 3905/4885AKT2 3986/4885AKT3 3951/4885 |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | AKT1 439/4885AKT2 335/4885AKT3 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.